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ABSTRACT Fibroblast growth factor-2 (basic FGF), a potent inducer of angiogenesis, and the naphthalene sulfonic
distamycin A derivative, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-
bis-(1,3-naphtalene disulfonate) (PNU145156E), which exhibits in vivo antiangiogenic activity, form a tight reversible (1:1)
complex. PNU145156E binds to the heparin and the selenate-binding sites on bFGF. The cis bFGF-heparin (2:1) complex,
essential for the activation of the angiogenic process, is thus prevented. The nature of the forces involved in bFGF:
PNU145156E complex, using the wild-type and the K128Q, K138Q, K134Q, and K128Q-K138Q point mutated bFGFs was
sought. Based on thermodynamic analysis of the complexation constants, protein temperature stability profiles by ultraviolet
absorption, circular dichroism measurements, fluorescence Fo¨rster energy-transfer, and anisotropy studies, in harmony with
the published x-ray crystallographic structure, the following molecular interactions are proposed: reduced coulombic
interactions, hence loosening of the complex by the removal of charged polar groups from the bFGF-heparin binding cleft
resulted in decreased binding constants and in a change in the binding mode from polar to nonpolar. Concomitantly, upon
mutation, the protein was rendered more compact, less flexible, and less aqueously exposed compared with the wild type.
These were further pronounced with the double mutant: weaker dominantly nonpolar protein-drug interactions were accom-
panied by conspicuous folding. With heparin, however, wild-type bFGF forms a tighter complex with a more compact
structure.
INTRODUCTION
Angiogenesis, the growth of new blood vessels, results from
a series of molecular events that are regulated by stimulators
and inhibitors (Klagsbrun and D’Amore, 1991). This pro-
cess is fundamental in the development, progression, and
metastatic spread of solid tumors (Folkman, 1971, 1985;
Folkman and Klagsbrun, 1987). A variety of tumor-induced
angiogenesis factors have been identified and are known to
have widespread effect on different steps of angiogenesis
(Gullino, 1978; Blood and Zetter, 1990; Liotta et al., 1991).
One important class of angiogenesis-promoting proteins is
the heparin-binding growth factors characterized by their
high affinity to heparan sulfate proteoglycans. Human fi-
broblast growth factors (FGFs) are the most important of
them (Burgess and Maciag, 1989; Biasoli et al., 1993; Presta
et al., 1994). X-ray crystallographic studies show that FGFs
take up a -trefoil structure with a cavity in its center
surrounded by hydrophobic residues (Eriksson et al., 1993).
This cavity that consists of three copies of basic four
stranded antiparallel -sheets is characteristic to the family
of -trefoil proteins. The same hydrophobic residues are
conserved in all of them, suggesting that the hydrophobic
interaction in the cavity play an important role in maintain-
ing the overall structure (Ogura et al., 1999). Chemical and
site-directed mutagenesis studies on basic FGF (bFGF) sup-
ported by x-ray crystallography have identified separate
functional domains for heparin and receptor binding (Baird
et al., 1988; Zhu et al., 1990, 1995; Eriksson et al., 1993; Li
et al., 1994; Springer et al., 1994; Thompson et al., 1994).
Various roles for the interaction of heparin and heparan
sulfate proteoglycans with bFGF have been proposed, in-
cluding stabilization of the protein, protection from proteo-
lytic degradation, extracellular storage, and most impor-
tantly, mediating the binding of bFGF to its cell surface
tyrosine kinase receptor (Yayon et al., 1991; Fernig and
Gallagher, 1994; Lindahl et al., 1994; Ornitz et al., 1995;
Faham et al., 1996; Venkataraman et al., 1996; Digabriele et
al., 1998; Plotnikov et al., 1999).
Studies on the activation of FGFs by heparin using sev-
eral model compounds (e.g., tetrasaccharide, hexasaccha-
ride, myoinositol hexasulphate (MIHS)) showed that the
binding to these analogs greatly increases the definition of
those regions of the protein recognized by the cell surface
tyrosine kinase receptors that trigger angiogenesis (Lozano
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et al., 1998; Ogura et al., 1999). This provided a mechanistic
explanation for the observed increase in the affinity between
FGFs and tyrosine kinase receptors in the presence of hep-
arin (Lozano et al., 1998; Ogura et al., 1999). Residues
involved in receptor recognition appear to be clustered in
two separate patches on the FGFs, namely, high affinity
receptors (HARs) binding sites and low affinity receptors
binding sites (Lozano et al., 1998).
It has been shown that the recognition of bFGF by HARs
requires the bFGF to be previously bound to heparin. The
binding to heparin induces conformational changes that
extend well beyond its binding site and affects the whole
structure of the protein. These changes cause a net decrease
in the flexibility of the protein, which affects the regions on
bFGF that interact with the HARs (Lozano et al., 1998).
Since the demonstration of the role of angiogenesis in can-
cer, the search for angiogenesis inhibitors has become the
focus of several research groups (Herblin et al., 1994; Auer-
bach and Auerbach, 1994). In the last few years, naphthalene
sulfonic distamycin-A derivatives were shown to inhibit the
binding of human recombinant bFGF to its receptors, to block
in vivo bFGF-induced vascularization and to stop neovascu-
larization in chorioallantoic membrane (Ciomei et al., 1993).
Suramin is one such polysulfonated naphthylurea that was
examined as a potential anticancer drug (La Rocca et al., 1990;
Kohler et al., 1992; Braddock et al., 1994; Manetti et al., 1998,
2000). Inhibition of FGF activity in the presence of suramin
has been attributed to the formation of nonspecific and irre-
versible protein aggregation. However, an important limitation
on the clinical use of suramin is the narrowmargin between the
dose required for antitumor activity and that leading to the
onset of prohibitive toxic side effects (Middaugh et al., 1992).
Therefore, any drug with similar antitumor activity as suramin
but substantial lower toxicity would be of considerable poten-
tial value. In this regard, a distamycin A derivative, (7,7-
(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-
methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphthalene
disulfonate)) - PNU145156E (suradista) was shown to inhibit
the growth of murine tumors with relatively low toxicity (Sola
et al., 1995, 1999). Unlike suramin, PNU145156E does not
cause caotropic aggregation of proteins. Our results on the
interaction between this drug and bFGF revealed a 1:1 tight but
reversible complex (Zamai et al., 1997, 1998). It is most likely
that this interaction covers a large surface of the protein in-
volving the heparin-binding domain described by Thompson et
al. (1994) and the selenate-binding site proposed by Eriksson et
al. (1993). Biologically effective dimerization of bFGF is me-
diated through heparin binding. The binding of PNU145156E
to bFGF prevents this dimerization. Structural information on
the interaction of suradista and suramin with FGFs is unavail-
able at present (attempts to crystallize the complex failed).
Gallego and co-workers have attempted structural analysis
using heparin and suramin functional analogs (MIHS and
naphthalene trisulfonate (NTS), respectively) (Pineda-Lucene
et al., 1998). They found that NTS and MIHS binding sites
partially overlap.
The intrinsic tryptophan fluorescence of the protein and
the weak drug fluorescence may be used to characterize the
protein-drug binding interactions. As opposed to other spec-
troscopic techniques that require much higher concentra-
tions of the interacting molecules, which eventually cause
aggregation, fluorescence detection requires micromolar
concentrations of the interacting molecules. Fluorescence
quenching of the protein (Trp) by PNU145156E and the
energy transfer band of PNU145156E were monitored to
quantify the binding interaction and to obtain the distance
information between the protein and the drug. Fluorescence
lifetime and anisotropy were used to compute the binding
constant and also the stoichiometry of the complex. In
addition, site-directed mutagenesis at the heparin-binding
site involving the residues identified by Eriksson et al.
(1993) (e.g., K128, K134, K138, and a double mutant of
K128-K138) should markedly affect the binding of the
drug. The change from each lysine (K) to glutamine (Q)
upon mutation reduces a single positive charge required to
neutralize the sulfates in the drug. The consequent loss of
electrostatic interaction should decrease the binding of the
drug on the putative docking site and affect both the thermal
stability and compactness of the protein. Temperature pro-
files of the binding curves were used to explore the kinetics
and thermodynamic stability of this complex. Finally, a
model of the protein-drug binding is proposed.
MATERIALS AND METHODS
Reagents and solutions
Suradista (PNU145156E), tetra sodium salt (molecular weight 1273, 98%
purity assessed by elemental analysis and nuclear magnetic resonance) was
obtained from Pharmacia and Upjohn (Milan, Italy). Human recombinant
fibroblast growth factor (bFGF) was purchased from PeproTech (Rocky
Hill, NJ). Its mutants K128Q, K138Q, K134Q, and K128Q-K138Q and the
heparin functional analog, -cyclodextrin tetradecasulfate (-CDS), were
prepared at A.Y.’s laboratory (Yayon et al., 1991; Li et al., 1994). Phos-
phate-buffered saline (PBS) contains 7.5 mM NaH2PO4, 17.5 mM
Na2HPO4, and 0.15 M NaCl (pH 7.1). A constant temperature bath (RTE-
111, Neslab Instruments, Inc., Newington, NH) with accuracy0.1°C was
used for temperature studies.
Fluorescence measurements
Steady-state fluorescence anisotropy and lifetime measurements were per-
formed on a fully automated frequency domain spectrofluorometer (ISS-
K2, ISS, Urbana-Champagne, IL) equipped with a 300-W Xenon arc lamp,
Glan polarizers, and a constant temperature bath. Samples were placed in
a 1-mm path cuvette (approximate volume of 100 L, Hellma, Jena,
Germany). For reference, we used TiO2 scattering solution. The emission
of tryptophan was collected using a Kodak UG1 filter that transmits light
above 320 nm. The noise levels were typically 0.3 to 0.5o in phase angle
and 0.005 to 0.010 in modulation. Data were analyzed by the ISS-K2
software. Fluorescence titration was performed for wild-type bFGF and its
mutants with increasing concentrations of PNU145156E in PBS. Total
sample absorptivity was lower or equal to 0.2 optical density. For anisot-
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ropy titration, the G factor was determined for correction. Quinine sulfate
(1 M in 0.1 N sulfuric acid) was used as the quantum counter. Steady-
state fluorescence and lifetime measurements were done at 25°C. Temper-
ature profiles of the binding were taken between 7°C and 35°C. Dynamic
polarization measurements for the bFGF:PNU145156E complex were per-
formed using the single photon counting setup at Prof. Elisha Haas’
Laboratory at Bar Ilan University (Gottfried and Haas, 1992; Haas, 1996):
(tryptophan, ex  295 nm, em  340 nm; PNU145156E, ex  350 nm,
ex  450 nm; energy transfer ex  295 nm, em  450 nm).
Determination of dissociation constants
Fluorescence steady state and lifetime titrations were used to determine the
dissociation constant (Kd) of bFGF:PNU145156E complex. bFGF concen-
tration was kept constant (0.31 M in PBS) with increasing PNU145156E
concentrations. The experiments were performed under equilibrium con-
ditions (Zamai et al., 1998). The model of simple bimolecular association
with ligand depletion was used to calculate binding constant (Hulme and
Birdsall, 1992). The binding curves at different temperatures were con-
structed for the wild type and two of the mutants (K128Q and K128Q-
K138Q). Values of Kd (or Ka) were determined using the Prism program,
from GraphPad Software Inc. (San Diego, CA).
Determination of R0
Fo¨rster distance, R0, is the distance between the donor and the acceptor for
a 50% efficiency of resonance energy transfer (Fo¨rster, 1965). This con-
stant is calculated using the spectroscopic properties of the donor and the
acceptor: a refractive index (nD) of 1.337 was used for PBS. The fluores-
cence quantum yield of the donor molecules was determined with reference
to quinine sulfate solution (in 0.1 N H2SO4) with a quantum yield of 0.55.
The spectral overlap integral J (M1 cm1 nm4) between the emission
spectrum of tryptophan residue in the protein and the absorption spectrum
of PNU145156E is given by:
J FDAA4	/FD	 (1)
The orientation factor (2) depends on the relative orientation of the
transition dipoles of the donor and the acceptor. The first estimation of the
Fo¨rster distance is obtained by fixing the isotropic dynamic average value
of 2  2/3 into the equation.
The ratio of steady-state fluorescence intensities for the donor only (ID)
and the donor in the presence of acceptor (IDA) is proportional to the
average energy-transfer efficiency 
E (equals 1, for 100% efficiency), as
described below:

E 1 IDA/ID (2)
The measured energy-transfer efficiency was used to calculate the average
distance 
R between the donor and the acceptor transition dipoles (see
legend of Table 3).
Estimation of the range of 2
From the measured emission anisotropy one can estimate the range of 2
using Eqs. 3 and 4 given by Blumberg et al. (1974) and Dale et al. (1979):

2max 2/31 
dDx 
dAx 3
dDx
dAx) (3)

2min 2/31 (
dDx 
dAx)/2] (4)
in which

dD,Ax rp/r0D,A1/2, (5)

dD,Ax is the donor or acceptor depolarization factor, rp is the experimen-
tally determined limiting anisotropy of either the attached donor or the
attached acceptor each excited at its absorption band, and r0 is the observed
fundamental anisotropy of either the free donor or the free acceptor. The
limiting anisotropy is independent of the rotational motion of the macro-
molecule and reflects the orientation of the attached chromophores. For
PNU145156E, 
dAx  1 (for a rigid binding). For the donor (tryptophan in
bFGF) 
dDx  (0.05/0.3)
1/2  0.41, using anisotropy values rp experimen-
tally obtained by us and r0 by Hansen et al. (1992).
Temperature dependence of binding kinetics
The change in the fluorescence intensity of tryptophan emission after the
addition of PNU145156E was monitored as a function of time at different
temperatures. A difference signal was collected after subtracting the fluo-
rescence of the sample from control.
Circular dichroism
Circular dichroism (CD) spectra of PNU145156E and bFGF, at different
concentrations, were recorded against the respective blanks by a J-715
spectropolarimeter (Jasco, Hanover, Germany), equipped with a 150-W
Xenon arc lamp, double polarized prisms monochromator Czerny-Turner
(from Acton Research, Acton, MA), and piezoelectric modulator. For
calibration, nonhygroscopic, water-soluble ammonium d-10-camphorsul-
fonate was used. Cuvettes of 1-mm optical pathway were used. Spectra of
bFGF (0.9–1.4 M) in PBS at variable pH in 290 L final volume were
recorded in the range of 195 to 260 nm. The titration to different pH was
obtained using 100 mM 3-([3-cholamidopropyl]-dimethylammonio)-1-pro-
panesulfonate for pH ranging between 7.7 and 9.8.
Thermal denaturation of bFGF
Thermal denaturation of bFGF was followed at 278 nm, applying a
gradient of 1°C/min from 27°C to 78°C and from 40°C to 90°C. The
enhanced ultraviolet absorption was monitored with a Perkin-Elmer (BSW,
Bodensewerk, Uberlingen, Germany) Lambda 11 spectrophotometer,
equipped with a temperature-controlled cuvette holder and an LKB 2219
Multitemp II Thermostatic Circulator (0.1°C), from Amersham Pharma-
cia Biotech (Uppsala, Sweden).
RESULTS AND DISCUSSION
Several amino acid residues in bFGF, Lys35, Asn36, Arg90,
Lys128, Arg129, Gln132, Lys134, Lys138, Gln143, and Lys144
(based on the sequence given in Eriksson et al. (1991, 1993)
and Thompson et al. (1994) and the numbering system
given by Li et al. (1994)) form the discontinuous epitope of
the binding site for heparin (Fig. 1). Residues 115 to 124,
presumed to bind to the receptor, include an irregular loop
that extends from the surface of bFGF and is 25 Å away
from the heparin-binding site. It is known that the above
lysine side chains form salt bridges with sulfate moieties in
heparin (Li et al., 1994). In a previous publication (Zamai et
al., 1998) we suggested that PNU145156E covers a large
surface of the protein that includes the heparin-binding
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domain described by Thompson et al. (1994) and the
selenate binding site proposed by Eriksson et al. (1993).
Steady-state fluorescence anisotropy measurements of
the binding between bFGF and PNU145156E resulted in a
saturation curve (Zamai et al., 1998; Fig. 2 A). To identify
the binding site of PNU145156E on bFGF, the heparin-6
(molecular weight 6000) was used in a competition study
(Fig. 2 B). Free PNU145156E in buffer solution, at the
concentration used for the binding studies, showed an an-
isotropy value of r  0.023  0.009. This value was not
altered in the presence of an equimolar concentration of
heparin-6. The addition of heparin to the bFGF:
PNU145156E complex resulted in a progressive decrease of
PNU145156E fluorescence anisotropy from 0.126  0.006
to that of the free ligand, 0.030  0.010 (Fig. 2), suggesting
that heparin displaces the drug from the complex, and
further supports the reversibility of the interaction. More-
over, 50% displacement occurs when the concentrations of
heparin and PNU145156E were approximately the same,
leading to relative Kd values of 142  16 and 54  6 nM
(mean  SD, n  8) for PNU145156E and heparin, respec-
tively. These results are expected in view of the similar
dissociation constants reported by Thompson et al. (1994)
for heparin, and by us for PNU145156E (Zamai et al.,
1998), obtained under similar ionic strength (Table 1).
These observations imply that both PNU145156E and hep-
arin compete for the same binding area, sharing at least one
binding site.
The good overlap between tyrosine (Fig. 3 A) or trypto-
phan (Fig. 3 B) emission spectrum and PNU145156E exci-
tation spectrum (Fig. 3 C) renders both donor-acceptor pairs
suitable for efficient Fo¨rster energy transfer. The 80% flu-
orescence quenching of the seven tyrosine residues in bFGF
by PNU145156E (shown in Fig. 4) resulted in a linear
Stern-Volmer plot (Fig. 4 inset). Because tyrosines 33, 112,
115, 120, 124, and 133 are located 15, 16, 17, 11, 13, and
10 Å, respectively, from the sulfonates binding site, and
tyrosines 82 and 115, 12 and 20 Å from the selenate
binding site (Fig. 1), they were expected to be efficiently
quenched. Therefore, whereas inner filter effects caused by
PNU145156E could contribute to the observed quenching,
energy transfer must play a major role. The quenching of the
single Trp123 was associated with an increase in the fluo-
rescence emission of PNU145156E at 440 nm, resulting
from energy transfer, Fig. 5. Because Trp123 is located 16
and 15 to 20 Å from the heparin and the selenate putative
FIGURE 1 X-ray structure of hu-
man bFGF, taken from the PDB
(Eriksson et al., 1993). Structure was
obtained at 1.6-Å resolution. The
protein was expressed in yeast (Sac-
charomyces cervisiae). Asterisks
(top) denote sulfate groups at the pre-
sumed heparin-binding site. The rel-
evant amino acids mentioned in the
manuscript are marked, including the
seven tyrosines and tryptophan-123.
Dark dots reflect water molecules.
The measured diameter of the protein
ranges from 34 to 40 Å.
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binding sites in bFGF, respectively (Fig. 1), the observed
energy transfer further support the hypothesis of a common
binding cleft for heparin and PNU145156E.
Three single mutants (K128Q, K134Q, and K138Q) and
a double mutant (K128Q-K138Q) in the heparin-binding
cleft were studied. Steady-state tryptophan fluorescence
quenching of wild-type bFGF and its mutants by
PNU145156E and by the heparin functional analog -CDS,
as well as steady-state and time-resolved fluorescence mea-
surements of PNU145156E, led to the binding constants
shown in Table 2. The magnitude of the Kd values revealed
that the same basic lysine residues that were identified to be
on the heparin-binding domain are also essential for binding
with PNU145156E. The replacement of each lysine residue
(K) in the single and the double mutants by neutral glu-
tamine (Q) resulted in an average of 5- to 10- and 30- to
40-fold decrease in the binding constants, respectively (Ta-
ble 2). This would translate to a G0 loss of 6 to 10 kJ
mol1 (Table 2). The similar change of G0 values, regard-
less of the site at which the positive charge is eliminated,
indicates that the binding is stabilized by the charge density
in the binding cleft, each charge contributes roughly 5 kJ
mol1 to the total binding interaction. That is, the electro-
static energy is about linear with the charge density on the
interacting surface.
Table 1 summarizes the Kd values for wild-type bFGF
and its mutants obtained by Thompson et al. (1994) and Li
et al. (1994) with heparin, and by us, with PNU145156E.
Whereas Thompson et al. (1994) and we used buffers with
similar ionic strength (150 mM) Li et al. (1994) results were
obtained at lower ionic strength (10 mM). For the sake of
comparison, Li et al. data were factorized for the ionic
strength of 150 mM, using the calibration curve shown in
Fig. 5 in Thompson et al. (1994). A direct comparison
between our and Thompson et al. (1994) results is justified
because both types of mutations used (alanine and glu-
tamine, respectively) resulted in the diminution of a single
positive charge per amino acid replaced at the binding cleft
of heparin. Inspection of the values obtained after correction
for the ionic strength reveals similar Kd values for heparin
(Li et al., 1994; Thompson et al., 1994), within the same
order of magnitude as our Kd values for PNU145156E.
Thompson et al. (1994) have found 37% contribution of
electrostatic interaction to the total binding interaction.
Comparison with our results, based on the linear correlation
obtained between the lifetime values of PNU145156E and
either Krygowski and Fawcett or Taft’s multiparameter
treatment of solvent polarity, revealed at least a similar
contribution from polar interactions (Zamai et al., 1998).
Additional support for the contribution of electrostatic in-
teractions is obtained from the effect of double mutation,
which, in free energy scale, is roughly additive. Thus, the
FIGURE 2 Binding of PNU145156E to bFGF (A) and displacement of
PNU145156E from PNU145156E:bFGF complex by heparin-6 (B).
Steady-state fluorescence anisotropy was measured at ex  350 and
em  440 nm in PBS, pH 7.1, at 20°C. [PNU145156E]  1.94 M;
[bFGF]  2.9 M.
TABLE 1 Comparison of dissociation constants associated
with the binding of PNU145156E and heparin to wild-type
bFGF and its mutants
bFGF
PNU145156E* Heparin† Heparin‡
(150 mM) (150 mM) (10 mM) (150 mM)
Kd (nM)
Wild type 127 (1)§ 470 (1) 2.3 214 (1)
K128Q 1230 (9.7) — 19.3 1796 (8.4)
K128A — 1670 (3.6) —
K134Q 1147 (9.0) — 0.4
¶
37 (0.2)
K134A — 7890 (16.8) —
K138Q 1157 (9.11) — 10.8 1008 (4.7)
K138A — 1460 (3.1) —
K128Q-K138Q 5115 (40.3) — 247.7 23,074 (107.9)
*The average values taken from Table 2.
†Taken from Thompson et al., 1994.
‡Taken from Li et al., 1994.
§Shown in parenthesis are factorized values in which the dissociation
constant obtained for the wild type, in each column, is presented as 1.
¶Additional studies have shown that the Kd value for K134Q reported by Li
et al. (1994) is questionable.
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electrostatic energy is about linear with the charge density
on the surface of binding.
Fo¨rster type energy transfer analysis was carried out with
the tryptophan-PNU145156E pair, in which the single tryp-
tophan at position 123 of bFGF acts as the donor and
PNU145156E acts as the acceptor. Fig. 6 shows the quench-
ing curves obtained for wild-type bFGF and its mutant. The
efficiency parameter of energy transfer 
E, was obtained by
extrapolating the quenching curves to binding saturation, as
described in Materials and Methods. Table 3 summarizes
these E values for the wild-type bFGF and its mutants. The
observed decline in E values upon single and double muta-
tions inversely correlates with the dissociation constants,
i.e., the lower the dissociation constant the higher is the
efficiency. This shows that the complex becomes weaker as
the number of positive charges and the corresponding cou-
lombic attractions are reduced. Attempts to calculate the
corresponding distances between PNU145156E and wild-
type bFGF and its mutants were based on the calculated
Fo¨rster distance R0  14.03 Å, using 
2  2/3, because
from the crystal structure of bFGF, the tryptophan chro-
FIGURE 3 Corrected fluorescence
spectra for the emission of bFGF and
for the excitation and the emission of
PNU145156E. The spectra were ob-
tained in PBS, pH 7.1, at 22°C. bFGF
(1.4 M), was excited at 274 nm (A)
and at 293 nm (B) for tyrosine and
tryptophan emission, respectively.
(C) PNU145156E (1.9 M); the two
excitation bands detected at 307 and
351 nm contributed equally to the
emission.
FIGURE 4 Quenching of bFGF-tyrosine fluorescence emission by
PNU145156E in PBS, pH 7.1, at 22°C. ex  274 nm; em  302 nm;
[bFGF]  1.15 M. The best nonlinear least-square fit, based on Hulme
and Birdsall (1992), is presented by the solid line. (Inset) Stern-Volmer
analysis based on: the solid line is the fitting to F0/F  1  Ksv
[PNU145156E], in which Ksv is the Stern-Volmer quenching constant.
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mophoric side chain is aqueously exposed and free to rotate
on the surface of the protein (Fig. 1). Regardless of its free
rotation, because of the rigid binding of PNU145156E, the
values of 2 could span from 0.2 to 2.4, which translate into
a range from R0((
2
max)
1/6) to R0((
2
min)
1/6)  (1.0 
0.2)R0, using Eqs. 3 and 4 (in Materials and Methods).
Table 3 presents the calculated R values. After mutation R
value increased by 20% in the single mutants and by
30% in the double mutant. Because the changes are small,
the tightness of binding is thus reflected: with more positive
charges and corresponding attractive coulombic interac-
tions, the distance between PNU145156E and tryptophan at
the binding cleft became shorter. Table 4 reports on the
rotational correlation times observed for free wild-type
bFGF and its mutants. These were practically identical and
averaged at 6.1  0.1 ns (mean  SD, n  4) and resulted
in similar radii values. Thus, it is suggested that no signif-
icant conformational changes occurred upon point mutation
in free bFGF. The displaced volume of the complexes,
24,200  400 Å3, was calculated from the rotational cor-
relation time, assuming a rotating sphere (Courtney and
Fleming, 1985). This was based on Stokes’-Einstein equa-
tion, 	  V
/kBT in which kB is Boltzmann constant, T is
the absolute temperature, V is the displaced volume of the
rotor, and 
 is the viscosity (1.02 cP). Because the aver-
age radius of wild-type bFGF and its mutants is 18.0  0.2
Å, it may be concluded that the overall dimensions of the
protein remains unaltered during mutation. This does not
exclude local conformational changes in the binding cleft.
FIGURE 5 Energy transfer in bFGF:PNU145156E complex. The in-
crease in PNU145156E fluorescence emission intensity at em  440 nm,
upon excitation at ex  293 nm (bFGF-tryptophan), was followed using
0.34 M bFGF in PBS, pH 7.1, at 22°C, as a function of [PNU145156E].
Energy transfer data analysis was carried out applying the one site binding
mode (hyperbola): A  (A[D])/Kd  [D]) in which A is the fluorescence
intensity, A is the maximal fluorescence intensity, and [D] is the molar
concentration of PNU145156E.
TABLE 2 Binding constants and associated free energies for the formation of bFGF:PNU145156E and bFGF:-CDS complexes
bFGF
bFGF:PNU145156E bFGF:-CDS
Kd* (nM) G
‡ G§
Kd
†
(nM) G G§
Q ET  Average (kJ mol1) Q (kJ mol1)
Wild type 120 119 143 127 39.42 — 118 39.52 —
K128Q 1080 1061 1551 1230 33.63 5.79 516 35.87 3.65
K134Q 1000 983 1459 1147 33.88 5.54 533 35.79 3.73
K138Q 972 832 1667 1157 33.73 5.69 546 35.73 3.79
K128-138Q 4924 5306 5286 5115 30.18 9.24 3207 31.34 8.18
Wild-type bFGF and its mutants, each at 0.31 M, were incubated in PBS with 0.01 to 2.5 M PNU145156E or 0.01 to 1.0 M -CDS at 25°C.
Dissociation constants were obtained by: Q, quenching of the Trp123-bFGF fluorescence emission at 340 nm, either by PNU145156E* or -CDS†, ex 
295 nm; ET, energy transfer to PNU145156E measuring fluorescence emission at 450 nm, ex  295 nm, and , lifetime of PNU145156E.
‡G0  RT ln [Kd(Mutant)/Kd(wt)].
§G0 is the difference between the average G0 values of mutants and wild-type bFGF.
FIGURE 6 Fluorescence quenching of wild-type bFGF and its mutants
by PNU145156E. The fluorescence emission of Trp123 of bFGF, wild-type,
and its mutants, each at 0.31 M, in the presence of variable concentrations
of the suradista, PNU145156E, in PBS, pH 7.1, was followed at 25°C,
ex  295 nm, em  340 nm. The efficiency of energy transfer was
obtained by extrapolating the quenching curves to binding saturation, as
described in Materials and Methods. (Inset) The fluorescence emission of
the double mutant K128Q-K138Q. Note the units of concentration in the
abscissa.
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The present study enabled us to compare the radius of
wild-type bFGF obtained by tryptophan fluorescence an-
isotropy with that of its complex, which was obtained by
PNU145156E fluorescence (Zamai et al., 1998). The in-
crease of 0.7 Å in the average radius of the complex (Table
4) may suggest that PNU145156E fits well into the binding
cleft, resulting in the proposed compact 1:1 complex (Zamai
et al., 1998). The values shown in Table 4 seem to demon-
strate that binding of PNU146156E to wild-type bFGF and
its mutants did not cause a major change in the overall
globular structure of the protein. Still, despite the uncer-
tainty in choosing the model of a rotating sphere as well as
the lack of significant differences between the radii values
of free and bound proteins, opposing trends between the
wild-type bFGF and its doubly mutated form upon compl-
exation may take place. In the temperature studies and the
corresponding thermodynamic analysis presented below,
these trends became conspicuous. The volume of the com-
plex with wild-type bFGF seems to expand relative to the
free protein while that of the doubly mutated one decreases,
suggesting differences in local conformational changes. It
should also be pointed out that the calculated hydrodynamic
volumes that revealed similar diameter values of36 Å, are
similar to that measured from the x-ray structure of the
protein (Eriksson et al., 1993), 34 to 40 Å (Fig. 1). The data
presented in Tables 3 and 4 fit well with the x-ray crystal
structure of bFGF (Fig. 1). One may notice that energy
transfer may occur between Trp123 and the naphthalenic
chromophores of PNU145156E, which are the two coulum-
bic hooks: one which is anchored to the selenate binding site
and the other is anchored to the heparin binding site, located
11 to 12 and 10 to 15 Å away, respectively. Based on
these findings, together with the results obtained upon the
carboxymethylation of bFGF (Zamai et al., 1998), the com-
petition with heparin (Fig. 2) and the increase in Kd values
upon mutation, the unique binding mode of the drug to both
the heparin and the selenate binding sites gains much
support.
To gain an insight into the conformational changes oc-
curring in bFGF upon binding to PNU145156E, CD mea-
surements were performed. bFGF has a CD spectrum with
a minimum at 205 nm. A strong effect on the 205-nm band
was observed upon the addition of PNU145156E at 22°C (in
PBS, pH 7.1; Fig. 7 A). The CD spectra as a function of pH
also showed decrease in molar ellipticity (not shown). The
effect caused by PNU145156E binding to bFGF resembled
that observed for the free protein at pH 9.5 (Fig. 7 B).
Ultraviolet hyperchromism at 278 nm as a function of
increasing temperature was used for studying the thermal
stability of the protein. Fig. 8 depicts the thermal denatur-
ation of wild-type bFGF in the presence of increasing con-
centrations of PNU145156E. A concentration-dependent in-
crease in the plateau was observed with 10°C shift of the
midpoint of the curves toward lower temperatures, i.e., from
a “melting temperature” Tm  62.2 to 53.1°C. A simple
two-state (folded-unfolded) model could not explain the
concurrent increase of the absorbance plateau. Therefore,
Tm values were calculated applying the Boltzmann’s equa-
tion (Cantor and Schimmel, 1980). Yet, a first order kinet-
ics, with t1/2  14.4 min, was revealed when isothermal
kinetic measurements were followed at 37°C by differential
absorbance spectroscopy at 278 nm. These may suggest that
conformational changes were induced upon PNU145156E
binding.
The effect of temperature on the binding of wild-type
bFGF and two of its mutants, K128Q and K128Q-K138Q,
with PNU145156E was studied. The values of the thermo-
dynamic parameters are shown in Table 5. van’t Hoff plots
(ln Ka versus inverse temperature, in the range of 5–45°C)
showed that upon increasing temperature the binding of
PNU145156E to wild-type bFGF and its mutants decreased,
resulting in distinctly different shapes (Fig. 9). For the
wild-type bFGF:PNU145156E complex, a concaved shape
TABLE 3 Energy transfer efficiency parameters (E) and
associated distances (R) obtained from steady-state
fluorescence studies for bFGF-bound PNU145156E
bFGF 
E* R† (Å)
Wild type 0.84 10.6
K128Q 0.62 12.9
K134Q 0.70 12.2
K138Q 0.67 12.5
K128Q-K138Q 0.58 13.3
*
E  [1  (IDA/ID)].
†R R0[(1
E)/
E]
1/6; R06  (8.79 10
25)(nD4	D
2JAD); J 3.2
1016 cm6 M1; nD  1.337 for PBS; 	D  0.13; 
2  2/3; R0  14.03
Å.
TABLE 4. Effect of PNU145156E binding to bFGF on the
radius (r) of the complex based on rotational correlation time
() measurements
bFGF
	*
(ns)
r†
(Å)
r‡
(Å)
Wild type 6.0 17.8
Wild type  PNU145156E 6.7§ 18.5¶ 0.7
K128Q 6.2 18.2
K128QPNU145156E 6.3 18.3 0.1
K138Q 6.2 18.2
K138Q  PNU145156E 6.4 18.3 0.1
K128Q-K138Q 6.1 17.9
K128Q-K138Q  PNU145156E 5.6 17.4 0.5
*Rotational correlation times are the average of time resolved single
photon anisotropy decay measurements for either bFGF alone (0.31 M) or
(where indicated) bFGF-bound PNU145156E (1.94 M), using ex  295
and 340 nm, and em 350 and 450 nm, for tryptophan and PNU145156E,
respectively, assessed at room temperature.
†Radii values obtained from the Stokes’ Einstein equation, 	  V
/kBT,
assuming a rotating rigid sphere, see text.
‡Difference between the average radii values of bound and free bFGF.
§Average includes the value published before, 6.56 ns (Zamai et al., 1998).
¶Based on the average shown in §.
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was revealed (Fig. 9 a); the single mutant K128Q-bFGF:
PNU145156E complex showed a linear plot (Fig. 9 b),
whereas the complex with the double mutant, K128Q-
K138Q-bFGF-PNU145156E, resulted in a convex shape
(Fig. 9 c).
The van’t Hoff equation
dln K/dT H/RT2 (6)
is usually integrated to give a linear dependence on inverse
temperature. When H is temperature independent
ln K ln Y HvH/RT (7)
in which K is the binding constant, Y is the intercept value
related to entropy, HvH is the so-called van’t Hoff en-
thalpy, R is the gas constant, and T is the absolute temper-
ature. If the enthalpy is assumed to depend linearly on
temperature, i.e., with a temperature-independent nonzero
heat capacity change (Cp), then
HvH Hr CpT Tr (8)
in which Hr is the enthalpy at the reference temperature Tr
(Tr has been chosen so that Hr is zero), then the integrated
van’t Hoff equation yields
ln K ln Kr Cp1 ln Tr Tr/T ln T	/R (9)
The solid lines in Fig. 9, a and c, were obtained by fitting
the data to Eq. 4 with the following parameters: ln Kr 
14.3, Tr  326 K and Cp  730 cal mol
1 K1 and ln Kr
 12.8, Tr  287 K and Cp  2170 cal mol
1 K1,
respectively. The solid line in Fig. 9 b was obtained from
linear regression of the van’t Hoff Eq. 2, assuming implic-
itly that the enthalpy is temperature independent (Cp  0).
These data produced HvH value of 3960 cal mol
1.
Based on the analysis given by Spolar and Record (1994),
the net entropy change at the characteristic temperature
where Sassoc
o  0 is assumed to consist of three contribu-
tions:
Sassoc
o  SHE
o  Srt
o  Sother
o (10)
in which Sassoc
o is the entropy change upon protein ligand
association, SHE
o is the contribution from the hydrophobic
effect, Srt
o is the contribution from rotational and transla-
tional changes, and Sother
o is mainly the contribution from
conformational changes. The enthalpy intercept of the en-
thalpy-entropy compensation plot (H vs. TS) gives the
enthalpy when Sassoc
o  0 (Fig. 10). This occurs at T 315
and 293 K and resulted in slopes  1.06 and 1.07, for the
wild-type bFGF and its double mutant, respectively. The
FIGURE 7 Effect of pH and binding to PNU145156E on the CD spectra
of bFGF. Spectra of bFGF, free (F), and PNU145156E-bound (E) re-
corded in PBS, pH 7.1, at 22°C (A) and at pH 9.5 (B). Spectra of
bFGF:PNU145156E complex, recorded in PBS, pH 7.1, at 22°C (A and B).
[bFGF]  [PNU145156E]  1.5 M.
FIGURE 8 Effect of PNU145156E on the thermal stability of bFGF. To
evaluate the thermal stability of bFGF, ultraviolet hyperchromism at 278
nm as a function of increasing temperature was obtained using 1.15 M
bFGF in the absence (1) and the presence of: 0.25 (2), 0.55 (3), 1.2 (4), 1.6
(5), 2 (6), and 2.6 (7) M PNU145156E. Each sample was preincubated at
room temperature for 1 h, then a thermal gradient of 1°C/min was applied.
Data were corrected for blank curves run at each ligand concentration.
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hydrophobic contribution as a function of temperature can
be estimated from Spolar and Record (1994):
SHE 1.35Cp lnT/386 (11)
The value 1.35 is an empirical factor found for protein
folding and may be assumed to reasonably apply for the
association of globular proteins with ligands (Faergeman et
al., 1996). For rigid body association, Srt
o 50 cal mol1
K1 (Table 3, in Spolar and Record, 1994). Finally, we
assumed that Sother
o  Sconf
o , which is an acceptable
assumption in protein ligand association processes. Accord-
ingly, we found that Sconf
o equals 250 and 360 cal mol1
K1 for the wild-type bFGF and its double mutant, respec-
tively. Furthermore, using the empiric relationship between
SHE
o and Anp (Spolar and Record, 1994)
SHE
o  0.32Anp ln T/386 (12)
in which SHE
o is the entropy change due to the hydrophobic
effect and Anp is the change in the nonpolar surface area of
the protein exposed to water. This area can be estimated, as
given in Table 5.
The single and double mutants of bFGF, characterized by
the reduction of one and two positive charges are progres-
sively less stable than the wild-type bFGF (Li et al., 1994;
Thompson et al., 1994). Binding of PNU145156E to wild-
type bFGF results in destablization of the complex, as is
evident from both the CD spectra (Fig. 7) and the temper-
ature stability profiles (Fig. 8). The negative value of Hs
for all three proteins implies an enthalpy driven reaction.
Based on Cp values obtained upon binding of
PNU145156E to the wild-type bFGF (Table 5), it is sug-
gested that partial defolding occurred. In contrast, the bind-
ing of PNU145156E to the double mutant resulted in a
negative Cp value, which may indicate folding into a more
TABLE 5 Thermodynamic parameters (G, Cp, H, and S) and changes in surface area (Anp) associated with the formation
of bFGF: PNU145156 complex
bFGF ln Kr*
† Tr* Gr* Cp Hs
‡ EECS§ SHE Sconf Anp
Wild type 14.3 326 9240 730 8510 1.06 (315 K) 200 250 3090
K128Q¶ 13.7 NA 8290 0 3960 NA 0 65 0
K128Q-K138Q 12.8 287 7260 1110 7210 1.07 (293 K) 410 360 4660
*Subscript r denotes that the respective value is given at the temperature (T(K)) in which HvH  0, and
†Kr is the association constant (nM
1); G, cal
mol1, Cp, cal mol
1 K1, H, cal mol1, S, cal mol1 K1, Anp, Å
2. ‡HS  H at S  0.
§EECS, enthalpy enthropy compensation slope. ¶Data
given for T  304K. H based on van’t Hoff equation (Eq. 6).
NA, not applicable.
FIGURE 9 van’t Hoff plots of the binding of wild-type bFGF and its
mutants to PNU145156E. Straight line has been obtained assuming that
Cp  0. [protein], 0.31 M; [PNU145156E], 1.94 M.
FIGURE 10 Enthalpy-entropy compensation plot. Data taken from Fig.
9 were used to obtain the H versus TS plots for the binding of wild-type
bFGF and its K128Q-K138Q mutant to PNU145156E.
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compact conformation (Spolar and Record, 1994). This
implies that the double mutant bFGF is more compact
compared to the wild-type bFGF. This gains additional
support from the change in entropy: the positive change in
the entropy of conformation, Sconf
o , upon complex forma-
tion with wild-type bFGF reflects the exposure of hydro-
phobic surface to water (meaning that water became less
ordered due to breaking of the structured hydrogen bonding
network in bulk water), and Anp increased by 3090 Å
2
(Table 5). With the double mutant however, Sconf
o value is
negative and accompanied by a decrease of 4680 Å2 in
Anp, which suggests the expulsion of protein-bound-water
to the bulk (Table 5).
The data in Fig. 9 were then correlated with the experi-
mentally determined distance between tryptophan and
PNU145156E based on energy transfer data analysis given
in Table 3: R  10.6 and 13.3 Å for the wild-type and
K128Q-K138Q bFGFs, respectively.
A proposed model of the interaction between bFGF and
PNU145156E is presented in Fig. 11 A. Herr’s sketched
model of bFGF binding to the octasaccharide molecule of
heparin, HS-8 (Herr et al., 1997; Waksman and Herr, 1998)
is shown in Fig. 11 B. The cis bFGF-heparin complex is
essential for bFGF binding to its receptor, a prerequisite for
the activation of the angiogenic process (Herr et al., 1997;
Waksman and Herr, 1998). In comparison, a proposed
model for the interaction between bFGF and PNU145156E
is shown in Fig. 11 A. PNU145156E binds to the cleft,
which extends from the heparin binding site (1) to the
selenate binding site, exploited by the protein for dimeriza-
tion (2 or 2) (Faham et al., 1996). Thus, the complexation
with PNU145156E that blocks heparin binding and prevents
protein dimerization can be a molecular level explanation
for its antiangiogenic activity.
Based on x-ray crystallography, bFGF is assumed to be a
sphere (Fig. 1). The bow-shaped PNU145156E with its
charged naphthalenic ends and the hydrophobic polypyrrole
skeleton in between may approach the wild-type protein in
an extended conformation (Fig. 11 A, left). Thus, the posi-
tive charges on the bFGF (depicted schematically by the
half circles on top of the protein) interact through coulombic
forces as anchors for the negative naphthalenic edges of the
bow shaped-PNU145156E serving as hooks. At least one
water layer is left in between. In this mode of binding the
distance between the donor Trp123 and PNU145156E ac-
ceptor chromophores was estimated from the energy trans-
fer experiments to be 10.6 Å (Table 3). With the double
mutant, PNU145156E approaches the protein sphere with
one of its negative naphthalenic moieties away from the less
positively charged heparin-binding edge (Fig. 11 A, right).
This negatively charged naphthalenic end is more exposed
to the water and thereby more effectively solvated. In this
mode, the distance from tryptophan to the naphthalenic
structures increases to 13.3 Å (Table 3). The polypyrrole
portion of the PNU145156E, in between the two charged
ends, interacts with the surface of the protein and through
hydrophobic interactions causes the so-called “induced fit.”
This renders the protein more compact and water molecules
are expelled from the interface of the hydrophobic surfaces.
Based on time-resolved fluorescence anisotropy studies, we
have found that PNU145156E at high concentrations, i.e.,
above 5 M, aggregates up to decamers (data not shown).
This occurs despite it being negatively charged, which
points to the strong hydrophobic forces that dominate the
formation of the aggregates. Accordingly, the interaction of
PNU145156E with the doubly mutated bFGF, in which two
positive charges have been eliminated, is primarily con-
trolled by hydrophobic interactions.
The results of both CD (Fig. 7) and temperature stability
(Fig. 8) measurements complemented the general picture
emerging from the thermodynamic and kinetic findings, i.e.,
that the wild-type bFGF is destabilized upon binding to
PNU145156E. The similarity between the CD spectrum of
free bFGF at pH 9.5, which is the isoelectric point, and that
obtained for the complex at pH 7.1, further supported this
proposed destabilizing-denaturation effect. Neutralization
of the positive charges on bFGF, be it by the negatively
charged PNU145156E or by hydroxylic moieties at the
basic pH, destabilizes the protein: free bFGF has a shape
distinct from either -sheet or -helix, perhaps a signature
of the compact three-dimensional -barrel structure (Eriks-
FIGURE 11 Proposed models for the interaction of PNU145156E and
heparin, HS-8, with bFGF. (A) Complexation between PNU145156E and
wild-type bFGF (left) and mutated bFGF (the substitution of the one-half
circles by a straight line on top of the protein represents the reduction in
positive charge) (right). (B) Herr’s sketched model of cis bFGF:HS-8
dimer (Herr et al., 1997; Waksman and Herr, 1998).
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son et al., 1993). Upon PNU145156E binding, destabiliza-
tion of the -barrel structure as bFGF approaches its iso-
electric point (pH 9.5) is thus proposed. It is known that
hydrophobic interactions in the cavity play an important
role in maintaining bFGF overall structure (Ogura et al.,
1999).
Similarly, PNU145156E binding resulted in 10°C de-
crease in the thermal stability of bFGF. These suggested that
binding of PNU145156E destabilizes the protein relative to
the free protein, which is in contrast to the increase in
stability of bFGF upon binding heparin. The binding to
heparin induces conformational changes that extend well
beyond its binding site and affects the whole structure of the
protein. These changes cause a net decrease in the flexibility
of the protein, which affects the regions on FGF that interact
with the HARs (Lozano et al., 1998). The more compact
structure obtained is thus suggested as a prerequisite for the
binding of bFGF to the receptor. The binding to
PNU145156E however, results in increased destabilization
and flexibility of the protein, presumably adding to its
reduced binding to the receptor. Similar observations have
been recently reported using nuclear magnetic resonance
studies of acidic-FGF (FGF-1) interaction with NTS, an-
other heparin analog (Lozano et al., 1998).
CONCLUSIONS
In our study we distinguish between two different effects of
the removal of charged polar amino acids. The first is the
decrease in the binding constant and the resulting loosening
of the complex, i.e., the complex turning less restricted in
space, adopting a shallower energy minimal profile. The
second is the effect induced by the drug upon protein
folding, which, with reduced surface charge, becomes more
compact and less flexible. In particular, the complex with
the wild-type bFGF is tight although the protein is destabi-
lized and turns more aqueously exposed and more flexible.
The double mutant however, portrays the other extreme: a
much weaker protein drug interaction is accompanied by a
pronounced folding into a more compact protein structure.
With heparin however, wild-type bFGF formed a tighter
complex yet rendered bFGF more compact and stable. The
partial denaturation induced by PNU145156E upon bFGF
further contributes to blocking bFGF biological activity.
This, together with PNU145156E blocking bFGF dimeriza-
tion, renders this drug a potentially efficient antiangiogenic
agent.
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